Log In
Friday 23rd February 2018

Revamp for transfusion service

20th July 2006

08052006_bloodtransfusion1.jpgA modernisation of the blood transfusion service has been announced, including the possible sale or closure of its Bio Products Laboratory (BPL), and almost certainly involving job losses among its 6,000-plus staff.

Better conservation of blood during operations has seen demand fall but unit costs rise, with additional screening adding to costs. Because of the risk of CJD the laboratory has had to buy plasma from the US, increasing its costs. The main therapeutic product it was set up to provide, factor VIII for haemophiliacs, has also been replaced by an artificial alternative. The authority is seeking international partners for a joint venture, supply contracts, or a possible sale, without which there is a real risk of closure. This would leave the UK dependent on overseas supplies of immunoglobulin and albumin.

On the transfusion side it is likely that the 10 processing plants covering England and north Wales will be reduced to three or four, and plans have already been announced to replace three plants with a £60m centre in Bristol.




Share this page


There are no comments for this article, be the first to comment!

Post your comment

Only registered users can comment. Fill in your e-mail address for quick registration.

Your email address:

Your comment will be checked by a Healthcare Today moderator before it is published on the site.

Mayden - Innovative cloud-based applications for healthcare
© Mayden Foundation 2018